Cargando…
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc a...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300912/ https://www.ncbi.nlm.nih.gov/pubmed/37376649 http://dx.doi.org/10.3390/v15061350 |
_version_ | 1785064688330997760 |
---|---|
author | Wang, Ruolan Wright, Jonathan Saggu, Parminder Ait-Khaled, Mounir Moodley, Riya Parry, Chris M. Lutz, Thomas Podzamczer, Daniel Moore, Richard Górgolas Hernández-Mora, Miguel Kinder, Clifford Wynne, Brian van Wyk, Jean Underwood, Mark |
author_facet | Wang, Ruolan Wright, Jonathan Saggu, Parminder Ait-Khaled, Mounir Moodley, Riya Parry, Chris M. Lutz, Thomas Podzamczer, Daniel Moore, Richard Górgolas Hernández-Mora, Miguel Kinder, Clifford Wynne, Brian van Wyk, Jean Underwood, Mark |
author_sort | Wang, Ruolan |
collection | PubMed |
description | The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot. A total of 320 (86%) participants on DTG/3TC and 318 (85%) on TBR had both proviral genotype data and ≥1 on-treatment post-baseline VL results and were defined as the proviral DNA resistance analysis population. Archived International AIDS Society–USA major nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, and integrase strand transfer inhibitor resistance-associated mutations (RAMs) were observed in 42 (7%), 90 (14%), 42 (7%), and 11 (2%) participants, respectively, across both groups; 469 (74%) had no major RAMs at baseline. M184V/I (1%), K65N/R (<1%), and thymidine analogue mutations (2%) were infrequent. Through week 144, >99% of participants on DTG/3TC and 99% on TBR were virologically suppressed (last on-treatment VL <50 copies/mL) regardless of the presence of major RAMs. Results from the sensitivity analysis by Snapshot were consistent with the last available on-treatment VL. In TANGO, archived, pre-existing major RAMs did not impact virologic outcomes through week 144. |
format | Online Article Text |
id | pubmed-10300912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103009122023-06-29 Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 Wang, Ruolan Wright, Jonathan Saggu, Parminder Ait-Khaled, Mounir Moodley, Riya Parry, Chris M. Lutz, Thomas Podzamczer, Daniel Moore, Richard Górgolas Hernández-Mora, Miguel Kinder, Clifford Wynne, Brian van Wyk, Jean Underwood, Mark Viruses Brief Report The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot. A total of 320 (86%) participants on DTG/3TC and 318 (85%) on TBR had both proviral genotype data and ≥1 on-treatment post-baseline VL results and were defined as the proviral DNA resistance analysis population. Archived International AIDS Society–USA major nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, and integrase strand transfer inhibitor resistance-associated mutations (RAMs) were observed in 42 (7%), 90 (14%), 42 (7%), and 11 (2%) participants, respectively, across both groups; 469 (74%) had no major RAMs at baseline. M184V/I (1%), K65N/R (<1%), and thymidine analogue mutations (2%) were infrequent. Through week 144, >99% of participants on DTG/3TC and 99% on TBR were virologically suppressed (last on-treatment VL <50 copies/mL) regardless of the presence of major RAMs. Results from the sensitivity analysis by Snapshot were consistent with the last available on-treatment VL. In TANGO, archived, pre-existing major RAMs did not impact virologic outcomes through week 144. MDPI 2023-06-11 /pmc/articles/PMC10300912/ /pubmed/37376649 http://dx.doi.org/10.3390/v15061350 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Wang, Ruolan Wright, Jonathan Saggu, Parminder Ait-Khaled, Mounir Moodley, Riya Parry, Chris M. Lutz, Thomas Podzamczer, Daniel Moore, Richard Górgolas Hernández-Mora, Miguel Kinder, Clifford Wynne, Brian van Wyk, Jean Underwood, Mark Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 |
title | Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 |
title_full | Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 |
title_fullStr | Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 |
title_full_unstemmed | Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 |
title_short | Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 |
title_sort | assessing the virologic impact of archived resistance in the dolutegravir/lamivudine 2-drug regimen hiv-1 switch study tango through week 144 |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300912/ https://www.ncbi.nlm.nih.gov/pubmed/37376649 http://dx.doi.org/10.3390/v15061350 |
work_keys_str_mv | AT wangruolan assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT wrightjonathan assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT sagguparminder assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT aitkhaledmounir assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT moodleyriya assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT parrychrism assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT lutzthomas assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT podzamczerdaniel assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT moorerichard assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT gorgolashernandezmoramiguel assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT kinderclifford assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT wynnebrian assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT vanwykjean assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 AT underwoodmark assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144 |